Literature DB >> 17720896

Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes.

Aaron P Kellogg1, Tim D Wiggin, Dennis D Larkin, John M Hayes, Martin J Stevens, Rodica Pop-Busui.   

Abstract

OBJECTIVE: Activation of the cyclooxygenase (COX) pathway with secondary neurovascular deficits are implicated in the pathogenesis of experimental diabetic peripheral neuropathy (DPN). The aim of this study was to explore the interrelationships between hyperglycemia, activation of the COX-2 pathway, and oxidative stress and inflammation in mediating peripheral nerve dysfunction and whether COX-2 gene inactivation attenuates nerve fiber loss in long-term experimental diabetes. RESEARCH DESIGN AND METHODS: Motor and sensory digital nerve conduction velocities, sciatic nerve indexes of oxidative stress, prostaglandin content, markers of inflammation, and intraepidermal nerve fiber (IENF) density were measured after 6 months in control and diabetic COX-2-deficient (COX-2(-/-)) and littermate wild-type (COX-2(+/+)) mice. The effects of a selective COX-2 inhibitor, celecoxib, on these markers were also investigated in diabetic rats.
RESULTS: Under normal conditions, there were no differences in blood glucose, peripheral nerve electrophysiology, markers of oxidative stress, inflammation, and IENF density between COX-2(+/+) and COX-2(-/-) mice. After 6 months, diabetic COX-2(+/+) mice experienced significant deterioration in nerve conduction velocities and IENF density and developed important signs of increased oxidative stress and inflammation compared with nondiabetic mice. Diabetic COX-2(-/-) mice were protected against functional and biochemical deficits of experimental DPN and against nerve fiber loss. In diabetic rats, selective COX-2 inhibition replicated this protection.
CONCLUSIONS: These data suggest that selective COX-2 inhibition may be useful for preventing or delaying DPN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720896     DOI: 10.2337/db07-0740

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  50 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

2.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 3.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

Review 4.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

5.  Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Hanna Shevalye; Hiroko Hirooka; Jerry L Nadler; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

6.  12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Alexander A Obrosov; Viktor R Drel; Jerry L Nadler; Irina G Obrosova; Mark A Yorek
Journal:  J Diabetes Mellitus       Date:  2013-08

Review 7.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

8.  New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.

Authors:  Viktor R Drel; Sergey Lupachyk; Hanna Shevalye; Igor Vareniuk; Weizheng Xu; Jie Zhang; Nicholas A Delamere; Mohammad Shahidullah; Barbara Slusher; Irina G Obrosova
Journal:  Endocrinology       Date:  2010-03-31       Impact factor: 4.736

Review 9.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 10.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.